Results from late-stage clinical trials indicate that a new medication offers significant relief for patients suffering from chronic obstructive pulmonary disease (COPD). The drug, known as tozorakimab and developed by AstraZeneca, appeared effective in lowering the frequency of moderate to severe COPD exacerbations among both current and former smokers.
These findings were presented Tuesday at the European Respiratory Society Congress and are scheduled for publication in a peer-reviewed medical journal. Dr. Frank Sciurba, a professor of Pulmonary and Critical Care Medicine at the University of Pittsburgh, noted in an AstraZeneca press release that tozorakimab represents the first biologic drug to demonstrate efficacy in treating COPD symptoms.
In two separate trials sponsored by the pharmaceutical giant, patients already utilizing standard inhaler regimens were divided into groups receiving either a 300-milligram injection of tozorakimab every four weeks or a placebo. The data revealed that the drug reduced COPD symptom exacerbations by between 29% and 34% in former smokers, and by 29% to 30% in the combined group of current and former smokers, compared to those who received the placebo.
The medication functions as a first-in-class monoclonal antibody that targets interleukin-33, a protein released by damaged cells that drives inflammation in conditions like COPD. AstraZeneca reported that tozorakimab was well-tolerated, with injection-site reactions being the only notable side effect.
Sharon Barr, executive vice president of BioPharmaceuticals R&D at AstraZeneca, stated that the results from these replicated trials set a new benchmark for treatment outcomes across a broad patient population. “AstraZeneca has validated the novel approach of targeting the two forms of IL-33 to both decrease inflammation and disrupt the cycle of mucus dysfunction,” Barr said.
The U.S. Food and Drug Administration (FDA) has accepted tozorakimab for priority review as an add-on maintenance therapy for adults with COPD, signaling an expedited pathway toward potential approval. The company is also investigating the drug’s potential application in asthma and other lower respiratory tract diseases.
COPD remains a critical public health issue in the United States, affecting nearly 16 million adults according to the Centers for Disease Control and Prevention (CDC). The disease, which includes emphysema and chronic bronchitis, is a leading cause of death and has no known cure. While tobacco smoke is the primary cause, the CDC notes that up to one in four COPD patients have never smoked.
My dad has COPD and hates his inhalers. If these shots work as well as the trials suggest, he might actually have hope again.
Prioritization by the FDA is good news, but I hope the cost doesn’t price out the very people who need this most.
A twenty-nine percent reduction is decent, but I wonder how that translates to actual daily quality of life for patients on the bus or stairs?
Wait, so up to one in four patients never smoked? This changes everything about how we understand and treat the disease.
This is a massive leap forward. Finally, a biologic specifically targeting the inflammatory pathway in COPD shows real promise.